IGF1 and cancer: For these reasons, inhibitors of IGF-1/R have been assessed as therapies for various cancers in clinical trials, although, as of 2023, only two—ceritinib and teprotumumab—have been approved by the United States Food and Drug Administration (FDA) for any indication [25,26].